Unmet Need:
- Gastrointestinal diseases such as colitis, Crohn’s disease, inflammatory bowel disease (IBD), and GI cancers often require aggressive drug therapies.
- Conventional treatments involve systemic drug absorption or to absorption throughout the full GI tract, leading to severe side effects due to non-targeted delivery.
- There is a critical need for GI – site-specific and on-demand drug release in the GI tract to improve efficacy and reduce adverse events
Our innovation:
- A remotely actuated oral tablet designed to release drugs upon exposure to an externally applied cue at the right time and at the right location.
- Figure: Targeted gastrointestinal drug delivery with time and site control via smart tablet technology
- This innovation is protected by US Provisional patent application
Advantages:
- Targeted drug delivery: Controlled release only at desired site via external stimulation.
- Reduced systemic side effects as well as effects in off target GI locations : Limits drug absorption to target region.
- Simple components no need for complex electronic: Uses edible, approved materials only.
- Distinct mechanism vs. prior art.
Commercial Opportunity:
- We are seeking collaboration with pharmaceutical or medical device companies to advance development and validation of this remotely activated oral drug delivery system.
- Potential applications include:
- IBD and GI oncology therapeutics.
- Personalized medicine platforms where location-specific activation is critical.
